Employing solid phase binding assays, rViscumin was shown to preferentially bind to terminally α2-6-sialylated neolacto-series gangliosides IV 6 Neu5Ac-nLc4Cer, VI 6 Neu5Ac-nLc6Cer, and VIII 6 Neu5Ac-nLc8Cer isolated from human granulocytes. Only marginal binding of rViscumin to galactose-terminated neutral GSLs was determined, whereas reinvestigation of ricin specificity demonstrated this lectin as a galactose-binding protein. Human promyelotic HL-60 cells exhibited an IC 50 value (half maximum cytotoxicity) of 1.16 pM and human bladder carcinoma 5637 cells of 12.1 pM rViscumin; CHO-K1 cells were resistant to rViscumin treatment up to a concentration of 5.26 nM tested. Quantification of the predominant receptor ganglioside IV 6 Neu5Ac-nLc4Cer by means of a specific anti-Neu5Acα2-6Galβ1-4GlcNAc-R antibody revealed 3.68 × 10 6 and 1.54 × 10 6 receptor molecules per HL-60 and 5637 cell, respectively; CHO-K1 cells were negative, lacking α2-6-sialylated gangliosides. The data imply a direct correlation of rViscumin cytotoxicity and the expression of receptor ganglioside. Moreover, CHO-K1 cells were rendered susceptible toward rViscumin cytotoxicity after exogenous application of human granulocyte gangliosides. Thus, (1) rViscumin has to be considered as a sialic acid-specific rather than a galactose-specific type II ribosomeinactivating protein, and (2) neolacto-series gangliosides with Neu5Acα2-6Galβ1-4GlcNAc-terminus are true functional and physiologically relevant rViscumin receptors.
Introduction
Proprietary mistletoe extracts are widely used as therapeutic immunomodulatory agents, mainly for oncological application in adjuvant therapy but also for general immunostimulation (Bocci, 1993; Hajto et al., 1990; Beuth, 1997) . Mistletoe lectin (ML) is a ribosome-inactivating protein of type II like ricin, abrin, and others (Barbieri et al., 1993) . Although these toxic proteins are of different phylogenetic origin, they share similar activities and structural properties (Eschenburg et al., 1998) , being potent inhibitors of eukaryotic protein synthesis at the ribosomal level (Glück et al., 1992) .
Three MLs with different carbohydrate specificities (ML-I, ML-II, and ML-III) have been isolated from mistletoe leaves. ML-I (also known as viscumin) was identified as the main therapeutic principle (Hajto et al., 1989; Beuth et al., 1993) . Unlike ricin, ML-I-containing extracts are medically applied for the treatment of human cancer. Viscumin is categorized as heterodimeric two-chain (type II) ribosome-inactivating protein, composed of a catalytically active A chain with RNA N-glycosidase activity and a B-chain with carbohydrate binding specificities (Olsnes et al., 1982; Franz, 1986 ) to yet undefined receptors on the surface of target cells. Recently, biotechnological production of recombinant ML (rViscumin) was achieved after cloning and separate expression of the single chains in Escherichia coli (Eck et al., 1999a,b) , yielding the active rML-heterodimer (Eck et al., 1999b) . The enzymatic A-chain activity and the carbohydrate binding activity of the B-chain are both essential for the cytotoxic apoptosis-inducing effect of the holoprotein as an anticancer drug (Langer et al., 1999) .
In numerous studies ML has been reported to belong to the group of galactoside-specific/lactose-binding lectins, which bind and cross-link certain multiantennary oligosaccharides, glycopeptides, and glycoproteins (Hajto et al., 1989; Gabius et al., 1992; Barbieri et al., 1993; Gupta et al., 1996) . Due to the lack of data concerning the potency of glycosphingolipids (GSLs) as lectin receptors, we investigated the binding specificity of rViscumin in comparison to ricin toward neutral GSLs and gangliosides.
GSLs are amphipathic molecules consisting of a hydrophilic oligosaccharide chain and a hydrophobic component named ceramide (Stults et al., 1989) . Gangliosides are characterized by the presence of one or more sialic acids in the oligosaccharide moiety, which are known to play crucial roles in various biological functions (Varki, 1992; Schauer et al., 1995) .
Gangliosides are involved in cell-cell recognition Hakomori, 2002) and adhesion by counterpart lectins (Schnaar, 1991; Feizi, 2001) and are well-characterized cellular attachment sites for viruses, bacteria, and exotoxins (Suzuki, 1994; Karlsson, 1989) . Employing naturally occurring GSLs of mammalian origin, we were able to show herein the preferential binding of rViscumin to α2-6-sialylated neolactoseries gangliosides and only marginal binding to galactoseterminated neutral GSLs. Consequently, rViscumin has to be considered as a sialic acid-specific rather than as a galactosespecific type II ribosome-inactivating protein, whereas reinvestigation of ricin specificity confirmed this lectin as galactose-specific.
Results
The first approach to obtain preliminary structural information regarding GSL binding specificities of rViscumin was to perform a screening by use of microwells coated with GSL mixtures of well-defined structures. Human erythrocytes are known to express globo-series neutral GSLs Gb4Cer and Gb3Cer, the former being the dominant one. Neutral GSLs of human granulocytes preferentially contain LacCer and the neolacto-series GSLs nLc4Cer, nLc6Cer, and to a lesser extent fucosylated derivatives of, for example, nLc6Cer, the so-called Lewis x -GSLs. By searching for certain ganglio-series neutral GSLs as potential receptors, a GSL mixture of MDAY-D2 cells was chosen due to its high content of Gg3Cer and Gg4Cer. Human brain gangliosides are suitable to investigate binding specificities of ganglio-series gangliosides, and human granulocyte gangliosides (HGGs) are the ideal candidates exploring the binding potency of terminally α2-3-and α2-6-sialylated neolacto-series monosialogangliosides.
Binding of rViscumin toward microwell adsorbed neutral GSLs and gangliosides
The microwell adsorption assays of rViscumin with three reference neutral GSL preparations (A, B, and C) and two ganglioside mixtures of well-known structures (D and E) are shown in Figure 1 . The only positive reaction within the neutral GSL fractions could be detected for neutral GSLs from human granulocytes, consisting of LacCer and nLc4Cer as the main compounds ( Figure 1B ). Of the two ganglioside fractions, human brain gangliosides were negative, but HGG revealed strong binding interaction with rViscumin ( Figure 1E ).
TLC overlay assay of rViscumin with granulocyte neutral GSLs and gangliosides
To identify the individual GSLs responsible for rViscumin binding, thin-layer chromatography (TLC) overlay assays with the faint positive neutral GSLs from human granulocytes and the strongly positive HGG were performed. The TLC-binding assay of rViscumin with neutral GSLs of human granulocytes revealed weak reaction with LacCer ( Figure 2A, lane b) , which represents the dominant GSL in this mixture. While LacCer (Galβ1-4Glcβ1-1Cer) was found to be at least a low-affinity binding ligand for rViscumin (see Table I ), the N-acetyl group of the penultimate GlcNAc completely abolished rViscumin binding toward nLc4Cer and nLc6Cer (both carrying the Galβ1-4GlcNAc-disaccharide at the nonreducing terminus). On the other hand, a fast and clear reaction could be achieved with HGG, uncovering two strongly stained double bands ( Figure 2B , lane b). Compared with the resorcinol stain of the respective lipids, the terminally α2-6-sialylated neolacto-series gangliosides IV 6 nLc4Cer and VI 6 nLc6Cer were suggested to represent the preferential receptors of rViscumin.
TLC overlay assays of anti-IV 6 nLc4Cer antibody and rViscumin with HPLC-separated neolacto-series gangliosides
To confirm this hypothesis, rViscumin binding assays were performed with high-performance liquid chromatography (HPLC)-separated HGG-fractions. Ganglioside fractions ( Figure 3A ) comprising IV 3 nLc4Cer (HGG1, lane c), VI 3 nLc6Cer (HGG2, lane d), IV 6 nLc4Cer (HGG3, lane e), and IV 6 nLc4Cer plus VI 6 nLc6Cer and VIII 6 nLc8Cer (HGG4, lane f) were chromatographed and overlayed with an antiNeu5Acα2-6Galβ1-4GlcNAc-R antibody, which has been raised by immunizing a chicken with IV 6 nLc4Cer. As shown in Figure 3B , the antibody specifically bound to IV 6 nLc4Cer, VI 6 nLc6Cer, and VIII 6 nLc8Cer of the HPLC fractions as well as to these gangliosides in the total HGG fraction. The isomeric structures IV 3 nLc4Cer and VI 3 nLc6Cer were not detected by this antibody. A further indication for the antibody specificity is shown in lane a of Figure 3B , where no crossreaction could be observed with any ganglio-series gangliosides. Exactly identical binding patterns compared to the antiNeu5Acα2-6Galβ1-4GlcNAc-R antibody were obtained in the TLC overlay binding assay with rViscumin ( Figure 3C ), exhibiting its high specificity toward monosialogangliosides with Neu5Acα2-6Galβ1-4GlcNAc-termini (see Table II ). Due to assaying ganglioside fractions isolated by gradient anionexchange HPLC, any cross-reactivities to, for example, "underlying" disialogangliosides or other lipid contaminants, which are absent in the HPLC eluates but might occur in the total HGG fraction, could be excluded. Thus, the most important and unexpected result of these binding assays is the fact that rViscumin is not a galactose-specific but a sialic acid-specific lectin with strict preference of the Neu5Acα2-6Galβ1-4GlcNAc configuration.
NanoESI-QTOF MS/MS of α2-6-sialylated gangliosides
The molecular ions of terminally α2-6-sialylated neolactoseries gangliosides obtained from the mass spectrometry (MS) spectrum of fraction HGG4 are listed in Table III . The most Figure 2A and of ricin see Figure 8 . * Appearance on immunostained TLCs graded from -(negative), (+) trace positivity, + weak binding up to +++++ highest intensity.
, anti-IV 6 nLc4Cer antibody TLC overlay assay (B), and rViscumin TLC overlay assay (C) with HPLC-purified α2-3-and α2-6-sialylated neolacto-series monosialogangliosides. Lanes a: 15 µg human brain gangliosides; lanes b: 15 µg human HGGs; lanes c: 4 µg IV 3 nLc4Cer (HGG1); lanes d: 4 µg VI 3 nLc6Cer (HGG2); lanes e: 4 µg IV 6 nLc4Cer (HGG3); lanes f: 8 µg IV 6 nLc4Cer, VI 6 nLc6Cer, and VIII 6 nLc8Cer (HGG4).
prominent ions (m/z 1516.83 and m/z 1626.93) belong to the monosialylated neolactotetraosylceramide species (Müthing et al., 1993) as expected from the orcinol stain ( Figure 3A , lane f) and the TLC immunodetection with the anti-Neu5Acα2-6Galβ1-4GlcNAc-antibody ( Figure 3B , lane f). The signal intensities of those with increasing molecular size (that is, with nLc6Cer-and nLc8Cer-cores) and those that have not been characterized in detail before were lower. All ganglioside components were characterized by ceramide parts containing in general two major fatty acid moieties for one core carbohydrate structure contributing to the complexity of the spectrum (not shown). For structural identification of nLc6Cer-and nLc8Cer-species, two molecular ions (m/z 1881.95 and m/z 2247.10, see Table III) were selected for low-energy collision-induced dissociation experiments. Their masses, together with the TLC immunostaining data were consistent with their assignment as being the gangliosides VI 6 Neu5Ac-nLc6Cer-and VIII 6 Neu5Ac-nLc8Cer-species, respectively, containing C 16:0 fatty acid in the ceramide portion. A series of high abundance Y-type ions is present in the tandem mass spectrometry (MS/MS) spectrum of the molecular ion (m/z 1881.95) of the heptasaccharide ceramide ( Figure 4A The fragmentation pattern in the spectrum of the molecular ion (m/z 2247.10) of the nonasaccharide ceramide is very similar to that of the heptasaccharide. A prominent Y-type ion series and a supporting but weaker B-type ion series provide corroborative evidence of an nLc8 core structure carrying a sialic acid moiety on its nonreducing terminus.
Biological activity of rViscumin
To investigate the cytotoxic ability of rViscumin on the cellular level, three cell lines with different biological background were employed to determine their cell-specific rViscumin sensitivity. Cultures of the human promyelocytic HL-60 cell line, consisting mainly of neutrophilic promyelocytes, exhibited the lowest IC 50 value (highest sensitivity) responding to 1.16 pM rViscumin with half maximum cytotoxicity ( Figure 5 ). The human 5637 cell line, representing small malignant cells with epithelial-like morphology and derived from bladder carcinoma, was one order of magnitude less susceptible corresponding to an IC 50 value of 12.1 pM rViscumin. Chinese hamster ovary (CHO-K1) cells, epithelial cells derived from a hamster ovary, were insensitive toward the cytotoxic action of rViscumin up to the highest concentration of 5.26 nM tested in this series of experiments. At concentrations of 0.175 nM rViscumin, both HL-60 and 5637 cells completely lost viability, whereas CHO-K1 Figure 9 . * Appearance of immunostained TLCs graded from -(negative), (+) trace positivity, + weak binding up to +++++ highest intensity. cells did not show any reduction in cell viability even at 30-fold higher concentrations.
Expression of rViscumin receptor ganglioside IV 6 nLc4Cer by in vitro propagated CHO-K1, 5637, and HL-60 cells
Gangliosides were isolated from the three cell lines with different sensitivity and their orcinol-stained thin-layer chromatograms are shown in Figure 6A . A simple doublebanded GM3 pattern is characteristic for CHO-K1 cells ( Figure 6A , lane b), lacking any higher gangliosides. In contrast to CHO-K1 cells, 5637 cells exhibited a couple of complex and yet unknown gangliosides ( Figure 6A , lane c). HL-60 cells were found to express rather low levels of gangliosides ( Figure 6A , lane d) but resembling the ganglioside profile of human granulocytes ( Figure 6A , lane a). The presence of IV 6 nLc4Cer in the ganglioside fractions of the three cell lines was investigated by use of the anti-IV 6 nLc4Cer antibody. For direct comparison, ganglioside amounts equivalent to 1 × 10 7 cells of each cell type were used for the TLC immunostain ( Figure 6B ). The rViscumin-resistent CHO-K1 cells were found to lack the receptor ganglioside, whereas 5637 and HL-60 cells express IV 6 nLc4Cer structures, which appear as double bands on the immunostained chromatogram. Owing to their identical TLC positions compared to IV 6 nLc4Cer of human granulocytes ( Figure 6B , lane a), upper bands of both cell lines represent the typical granulocyte gangliosides IV 6 nLc4Cer with C24-fatty acid (compound 1) and lower bands IV 6 nLc4Cer with C16-fatty acid (compound 2). Applying 134 ng of total HGG, the absolute amounts of compound 1 (26% of total HGG) and compound 2 (13.3% of total HGG) of lane a in Figure 6B correspond to 34.8 ng and 17.8 ng, respectively. Deduced from the TLC overlay assay, CHO-K1 cells were receptor-negative and HL-60 cells exhibited considerably higher quantities of IV 6 nLc4Cer compared with 5637 cells. These findings are in excellent agreement with rViscumin resistance of CHO-K1 cells and the significantly higher rViscumin sensitivity of HL-60 cells in comparison to 5637 cells (see Figure 5 ), pointing to an obvious correlation of cellular sensitivity and expression of receptor gangliosides.
Quantification of receptor ganglioside IV 6 nLc4Cer in 5637 and HL-60 cells
To calculate the absolute amounts of IV 6 nLc4Cer receptor gangliosides per single cells, TLC immunostained bands of defined cell numbers, ranging from 1 × 10 6 to 2 × 10 7 cells, were quantified by densitometry with the aid of HGG calibration curves. Based on the molecular weights of IV 6 nLc4Cer with C24-fatty acid (compound 1, MW = 1626) and IV 6 nLc4Cer with C16-fatty acid (compound 2, MW = 1516) and Avogadro's constant, the absolute molecule numbers per single cell were determined for 5637 and HL-60 cells (see Table IV ). For 5637 and HL-60 cells 1.54 × 10 6 and 3.68 × 10 6 IV 6 nLc4Cer (compound 1 plus compound 2) receptor molecules per cell were revealed, respectively. As a final result, the absolute amount of IV 6 nLc4Cer was 2.4-fold higher in HL-60 compared to 5637 cells. This data is in excellent agreement with the enhanced cytotoxicity of rViscumin toward HL-60 cells (see Figure 5 ).
Generating CHO-K1 cell susceptibility toward rViscumin by exogenous gangliosides
Gangliosides added exogenously to culture medium are taken up by a wide range of cells in vitro (Saqr et al., 1993) and incorporated into the plasma membrane by a time-and concentration-dependent process (Radsak et al., 1982) . CHO-K1 cells have been found to express predominantly GM3 ( Figure 6A , lane b). Other gangliosides are either absent or present only in trace quantities. Attempts were made to render CHO-K1 cells susceptible toward rViscumin. For that purpose, increasing amounts of HGG harboring the rViscumin receptor IV 6 nLc4Cer as the prevalent ganglioside were applied to CHO-K1 cell cultures and allowed to incorporate. As shown in Figure 7 , incubation of CHO-K1 cells with increasing concentrations of HGG prior to rViscumin treatment reduced the cell viability in a concentration-dependent manner. Cells prewashed with serum-free medium before rViscumin application revealed viabilities decreasing from 85.7% down to 31.5% (relative to control cultures without gangliosides and rViscumin) after incubation with 25 µM up to 200 µM HGG, respectively. Prewashing with serum-supplemented medium enhanced the cytotoxic effect leading to somewhat diminished viabilities at the respective HGG concentrations. Gangliosides alone had no effect on CHO-K1 cells up to a concentration of 100 µM; after treatment with 200 µM HGG viability was slightly decreased by about 12% compared to control cultures without gangliosides. From this data it was concluded that insertion of the receptor ganglioside IV 6 nLc4Cer from HGG, which represents the major ganglioside with Neu5Acα2-6Galβ1-4GlcNAc terminus in Table II and for quantification of IV 6 nLc4Cer by TLC immunostaining with anti-IV 6 nLc4Cer antibody see Table IV. the mixture, turned CHO-K1 cells from rViscumin-resistant to -sensitive cells, thereby confirming the biological function of IV 6 nLc4Cer as a true and physiologically relevant rViscumin receptor.
TLC overlay assay of ricin with neutral GSLs and gangliosides
Ricin (Ricinus communis lectin) is well accepted to represent a type II ribosome-inactivating protein with galactose specificity. This was tested with the same set of GSL references used for exploring rViscumin binding specificity. The orcinol stain ( Figure 8A ) and the parallel TLC-binding assay of ricin with neutral GSLs disclosed a weak staining of LacCer (Galβ1-4Glcβ1-1Cer) in all three reference mixtures ( Figure 8B ). The N-acetyl group of the penultimate GlcNAc obviously increased the strength of binding to nLc4Cer and nLc6Cer (both with Galβ1-4GlcNAc terminus) as shown in lane b of Figure 8B ( Table I) . Fucosylation of the nLc6Cer-core completely abolished ricin binding, indicated by failed recognition of Lewis x -GSL. Significant but less intensive ricin adhesion compared to, for example, nLc4Cer, was observed for Gg4Cer bearing the Galβ1-3GalNAc-disaccharide at the nonreducing end of the oligosaccharide sequence. Gb4Cer (GalNAcβ1-3Gal terminus) was negative and Gb3Cer (Galα1-4Gal terminus) exhibited weak signals. The order of binding preference of ricin toward neutral GSLs, deduced from TLC immunostainings, were the sequences Galβ1-4GlcNAc > Galβ1-3GalNAc > Galβ1-4Glc > Galα1-4Gal. Finally, TLC ricin overlay assays performed with gangliosides gave negative results for all terminally sialylated ganglio-and neolacto-series gangliosides ( Figure 9B) . A faint positive reaction was observed for GM1, a Gg4Cer-core ganglioside with Neu5Ac bound to the internal position II of the tetraosylbackbone. Sialylation at position IV of Gg4Cer (GD1a) and the disialo group Neu5Acα2-8Neu5Acα2-3R at position II of Table I .
GD1b, completely prevented ricin binding. Most important with regard to rViscumin specificity, no binding to any neolactoseries gangliosides could be observed as indicated by unstained white bands in the intentionally overstained background of the TLC immunoassay plate ( Figure 9B ). According to the data of these TLC immunostaining investigations, ricin can be unequivocally considered as a galactose-binding lectin, clearly distinguishable from rViscumin, which was shown to represent a sialic acid-specific lectin.
Discussion
The first step in the biological action of viscumin (ML-I) is recognition and binding of specific ligands on the surface of target cells. When glycoproteins with a complex pattern of glycosylation serve as source for the presentation of glycoligands, the individual contribution of each epitope is difficult to discern. Consequently, a huge number of binding and inhibition assays with chemically well-defined model ligands have been performed to better understand the initial process of ML-I adhesion. For that purpose, carbohydrate binding specificity of the galactose-binding ML-I was studied by competetive inhibition with monosaccharides, monosaccharide derivatives, disaccharides, and compounds containing multiple galactosyl terminals (Lee et al., 1992; Möckel et al., 1997) . It was found that ML-I has a broad range of affinity for Galα-and Galβ-linked sequences, revealing primarily recognition of the terminal galactose unit irrespective of the anomeric linkage (Lee et al., 1994; Gupta et al., 1996) . Although the conformational parameters of derivatized neutral disaccharide ligands before and after complex formation with the galactose-binding Viscum album lectin have been studied in detail (Gilleron et al., 1998) , little is known about the interaction of ML-I with naturally occuring sialooligosaccharides and sialoglycoproteins. The precipitability of human α1-acid glycoprotein and fetuin with ML-I was considerably decreased after desialylation (Wu et al., 1995) , but on the contrary the poor reactivity of rat sublingual sialoglycoprotein with ML-I increased substantially after removal of sialic acid. The inhibition of the glycoprotein-lectin interaction by Neu5Acα2-3/α2-6Galβ1-4Glc was taken as evidence that ML-I is specific for sialic acid. Substitution of the N-acetyllactosamine sequences of oligosaccharides and glycopeptides by sialic acid residues either at O-3 or O-6 of galactose was found to slightly enhance the affinity of ML-I (Debray et al., 1994) .
Following the approach with chemically well-defined model ligands (Lee et al., 1992) , a panel of strictly defined neoglycoconjugates and synthetic oligosaccharides were systematically tested to determine their individual binding and inhibitory potency (Galanina et al., 1997) . Among the two natural isomers of sialyllactose, the α2-6 form displayed a higher level of inhibitory capacity than the α2-3 derivative. However, from all these highly sophisticated binding and inhibition assays performed so far, the natural ligands on immunomodulatory potent and/or tumor target cells being responsible for B-chainspecific binding of the ML remained yet unidentified and rather obscure.
Among all the gangliosides tested in this study, terminally sialylated neolacto-series gangliosides with a Neu5Acα2-6Galβ1-4GlcNAc epitope at the nonreducing terminus, which have been isolated from human granulocytes, were the exclusive targets for rViscumin-mediated adhesion. The isomeric gangliosides with Neu5Acα2-3Galβ1-4GlcNAc sequences and neutral GSLs with Galβ1-4GlcNAc epitope were devoid of binding activity. LacCer (Galβ1-4Glcβ1-1Cer) was found to be the only, but rather slightly interacting neutral GSL with marginal receptor potency in comparison to α2-6-sialylated gangliosides. However, α2-6-sialylated lacto-series gangliosides with Galβ1-3GlcNAc-core cannot be excluded as possible rViscumin ligands at this stage of research. This aspect of further receptor characterization is a part of our future investigations.
Cancer cells are often characterized by the presence of "tumor-associated" GSL-antigens, and major progress has been made over the past two decades on structural identification of these antigens (Hakomori, 1998) . None of these structures are truly tumor-specific, and many GSLs to which antitumor antibodies responses are directed are also found in normal tissues. However, a large number of anti-GSL antibodies showed specific or preferential reactivity with tumor cells and no reactivity with normal cells or tissues, based on organizational differences of membrane GSLs in tumor cells versus normal cells. To elucidate the potential role of terminally α2-6-sialylated gangliosides as tumor-associated antigens, careful (re)investigations of rViscumin-susceptible tumor cell lines and/or tumor tissues has to be performed with regard to their specific expression of neolacto-series gangliosides with Neu5Acα2-6Galβ1-4GlcNAc-epitopes.
Following cell surface binding of V. album lectin and ensuing signaling, several cellular responses (such as secretion of cytokines, namely, tumor necrosis factor-α, interleukin-1, and interleukin-6 by human peripheral blood mononuclear cells) can be measured in the nontoxic dose range in vitro and in vivo (Hajto et al., 1990; Gabius et al., 1992; Möckel et al., 1997; Stein et al., 1998; Ribéreau-Gayon et al., 1997) . Specific immune responses against tumor-associated antigens mediated by T lymphocytes and nonspecific immune responses induced by cells of the mononuclear phagocyte system and natural killer cells appear to participate in naturally acquired resistance against neoplastic diseases. Studies on animals and humans proved that ML-I causes significant increase and activation of natural killer cells and enhances phagocytotic activity of granulocytes and monocytes (Hajto et al., 1989 (Hajto et al., , 1990 . T cell activation and preferential expansion of CD8 + T cells mediating Table II. the cytotoxic effect has been reported as well (Baxevanis et al., 1998) . The question currently remains unanswered of which type of oligosaccharides, that is, protein-or lipid-bound, is recognized by ML-I and may be responsible for eliciting the enumerated immunoresponses. Concerning the sialic acid specificity of MLB, amino acid sequencing (Huguet Soler et al., 1998) and molecular cloning of the B-chain in E. coli (Eck et al., 1999b) led to the speculation that rViscumin possesses at least three binding sites, as recently described for ricin (Frankel et al., 1996; Steeves et al., 1999) .
Finally, emphasizing the functional importance of receptor clustering described for neoglycoconjugates (André et al., 1997) , GSLs and particularly gangliosides are ideal candidates to fulfill the requirements for being effective rVscumin receptors. We presented a body of data that α2-6-sialylated gangliosides might be involved in B-chain-dependent signal triggering, thereby truly resembling cellular targets for rViscumin acting as B-chain-mediated immunomodulator and cytotoxic agent.
Materials and methods

Mass production of cells
CHO-K1 cells (ATCC CCL-81) and HL-60 cells (promyelotic human leukemia cell line, ATCC CCL-240) were cultivated with an 1:1 mixture of Dulbecco's modified Eagle medium (DMEM) and Ham's F12 medium and the human bladder carcinoma cell line 5637 (ATCC, HTB-9) in RPMI 1640. The cells were routinely passaged in conventional culture flasks (Nunc, Wiesbaden, Germany) at 37°C in a humidified 5% (v/v) CO 2 air-atmosphere. The media were buffered with 2.1 g/L NaHCO 3 and supplemented with 10% fetal calf serum (v/v). Cells were grown in the presence of 50 mg/L gentamycin and 2.5 mg/L amphotericin B.
Cell production of 5637 cells was performed in 175-cm 2 culture flasks. HL-60 and CHO-K1 cells were produced in a 1-L SuperSpinner (B. Braun Biotech International, Melsungen, Germany) equipped with a membrane stirrer for optimized oxygen supply of the cells (Heidemann et al., 1994) . CHO-K1 cells were propagated on Cytodex-1 microcarriers (Amersham Pharmacia Biotech, Uppsala, Sweden) as described in detail by Duvar et al. (1996) and Müthing et al. (1996b) . The physiological set points for spinner cultivations were: 37°C; pH 7.2; aeration with air; stirrer 40 rpm. After reaching the final cell densities, the cells were harvested and washed twice with phosphate buffered saline (PBS) before chloroform/methanol extraction.
Cytotoxicity assay
Cell viability and in vitro cytotoxicity were assayed using 4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate (WST-1, Roche Diagnostics, Mannheim, Germany). Cytotoxicity of rViscumin was analysed with HL-60, 5637, and CHO-K1 cells. Medium for HL-60 cells was serum-free X-Vivo 15 (Biowhittaker, Walkersville, MO), RPMI 1640 with 2.5% fetal calf serum for 5637, and DMEM/F12 with 1% fetal calf serum for CHO-K1 cells. Indirect measurement of cell viability was achieved by conversion of the soluble sulfonated tetrazolium salt into formazan by cells according to Ishiyama et al. (1993) . Samples were tested in six replicates, and the absorbance was determined at 450 nm for each well.
To assay cytotoxicity, 8 × 10 3 5637, 1 × 10 4 CHO-K1, or 1.8 × 10 4 HL-60 cells, respectively, were seeded per well in 96-well tissue culture plates (Nunc) and incubated with rViscumin in a final volume of 100 µl for 72 h at 37°C. For treatment, an adequate concentration range of rViscumin was chosen according to the sensitivity of the respective cell line (see Figure 5 ). After 72 h 10 µl WST-1 solution were added to the cell cultures and incubated for 3-4 h at 37°C. The amount of dye, which is proportional to the number of viable cells, was measured in a microwell plate reader (THERMOmax, Molecular Devices, Munich, Germany).
rViscumin, ricin, and anti-lectin antibodies
The heterodimeric recombinant ML (rML) rViscumin, composed of rMLA (A-chain) and rMLB (B-chain) (Eck et al., 1999b) , was used for analyzing binding specificity toward neutral GSLs and gangliosides in microwell adsorption and TLC overlay binding assay. GSL-bound rViscumin was detected with the mouse IgG monoclonal anti-rMLA antibody TA5 (Tonevitsky et al., 1995) .
R. communis lectin (ricin) was a kind gift of Dr. F. Stirpe (University of Bologna, Italy). Polyclonal rabbit anti-ricin antibody was purchased from Sigma-Aldrich Chemie GmbH (Traunstein, Germany; catalog no. R-1254).
rViscumin and ricin are highly potent toxins when reaching the body via the parenteral route (intravenous, subcutaneous, and intramuscular), whereas the enteral route (oral) toxicity is relatively low. Thus, handling of both substances should be done with utmost care, using gloves and avoiding highly concentrated working solutions and sharp or pointed tools.
Generation of rViscumin-susceptible CHO-K1 cells by exogenous gangliosides
The rViscumin-resistant CHO-K1 cells were tested for change in sensitivity to rViscumin after exogenous application of gangliosides in cell cultures. Cells were seeded at a density of 5 × 10 3 cells per well into a 96-well plate in serum-free CHO-1 medium (Biowhittaker, MD) and cultured for 24 h. The medium was then withdrawn and replaced by CHO-K1 medium containing 0 (control), 25, 50, 100, and 200 µM, respectively, of a preparation of total HGG. Gangliosides were allowed to incorporate into cells for 48 h under culture conditions at 37°C. After this incubation the cells were extensively washed either with serum-free or 5% fetal calf serum-containing CHO-K1 medium, followed by a 48-h treatment with 5.26 nM rViscumin. Viability was examined by WST-1 staining as described in comparison to untreated control cultures (without gangliosides and rViscumin). All cell culture assays were performed in triplicate in 100 µl volumes per well.
Isolation of GSLs from in vitro cultivated cells
GSLs from in vitro propagated cells were isolated according to standard procedures (Ledeen and Yu, 1982) and as described in detail by Duvar et al. (1997) . Gangliosides were isolated by anion exchange chromatography on DEAE-Sepharose CL-6B (Pharmacia Fine Chemicals, Freiburg, Germany) as reported by Müthing et al. (1987) . The ganglioside fractions were incubated for 1 h at 37°C in aqueous 1 N NaOH to saponify phospholipids followed by neutralization with acetic acid and dialysis. Gangliosides were further purified by adsorption chromatography on Iatrobeads 6RS-8060 (Macherey-Nagel, Düren, Germany) as described by Ueno et al. (1978) .
Reference neutral GSLs and gangliosides
Neutral GSLs from human erythrocytes (globo-series), human granulocytes (neolacto-series), and murine MDAY-D2 cells (ganglio-series) served as references for microwell adsorption assays and TLC overlay binding assays. Neutral GSL fractions contained (in the order of the relative amounts in each fraction starting with the dominant compound) Gb4Cer, Gb3Cer, and LacCer (erythrocytes); LacCer, nLc4Cer, nLc6Cer, and Le x -GSL (granulocytes; Müthing and Kemminer, 1996); and Gg4Cer, Gg3Cer, and LacCer (MDAY-D2; Schwartz et al., 1985; Müthing and Cacic, 1997) .
A ganglioside mixture containing GM3, IV 3 nLc4Cer, IV 6 nLc4Cer, and VI 3 nLc6Cer as the major constituents was isolated from human granulocytes (total HGGs) as previously described (Müthing et al., 1993 (Müthing et al., , 1996a .
A preparation of human brain gangliosides, composed of GM1, GD1a, GD1b, and GT1b, was purchased from Supelco (Bellefonte, PA).
Anion-exchange HPLC separation of terminally α2-3-and α2-6-sialylated neolacto-series gangliosides
For the separation of α2-3-and α2-6-sialylated monosialogangliosides HPLC was carried out with the Superformance universal glass-cartridge device of Merck, earlier published in detail (Müthing and Unland, 1994; Müthing, 2000) . A glass cartridge (150 mm × 10 mm) filled with Fractogel EMD TMAE-650(S) (Merck, No. 20286) was loaded with total gangliosides from human granulocytes (= HGG, see previous methods). TMAE-Fractogel-bound gangliosides were eluted with a linear ammonium acetate gradient, pooled, and desalted. Four fractions were obtained, comprising terminally α2-3 sialylated (HGG1 and HGG2) and terminally α2-6-sialylated neolacto-type monosiaolgangliosides (HGG3 and HGG4). The fractions HGG1 and HGG2 contained IV 3 nLc4Cer and VI 3 nLc6Cer, respectively. IV 6 nLc4Cer represents the only compound in fraction HGG3. HGG4 contained IV 6 nLc4Cer and VI 6 nLc6Cer plus minor quantities of VIII 6 nLc8Cer. All gangliosides separate as double bands on thin-layer chromatograms due to substitution of the sphingosine moiety with C24-(upper band) and C16-fatty acid (lower band). The structures of IV 3 nLc4Cer, IV 6 nLc4Cer, and VI 3 nLc6Cer have been determined by fast atom bombardment-MS and methylation analysis, as described elsewhere (Müthing et al., 1993) . The terminally α2-3-sialylated gangliosides IV 3 nLc4Cer and VI 3 nLc6Cer have been reinvestigated by electrospray ionizationquadrupole time-of-flight MS (ESI-QTOF-MS) as recently reported (Metelmann et al., 2000) . Terminally α2-6-sialylated gangliosides VI 6 nLc6Cer and VIII 6 nLc8Cer were structurally characterized in this study by ESI-QTOF-MS (see the following section).
ESI-QTOF-MS
Gangliosides of HPLC-purified fractions HGG3 and HGG4 were analyzed by nanoESI-MS and MS/MS using a QTOF mass spectrometer (Micromass, Manchester, UK) equipped with a nanospray manipulator. Negative ion mode was used exclusively for the ganglioside analysis. After selecting the precursor ion of interest with the first quadrupole, collision-induced dissociation was applied to obtain fragment ions for MS/MS sequencing (for details see Metelmann et al., 2001) . The nomenclature introduced by Domon and Costello (1988) was used for assignment of fragment ions.
Polyclonal anti-Neu5Acα2-6Galβ1-4GlcNAc-R antibody
At the age of 12 weeks a chicken was immunized according to the method of Kasai et al. (1980) . HPLC-purified IV 6 nLc4Cer was prepared from human granulocytes as described. One milligram of the ganglioside was adsorbed to 1 mg permethylated bovine serum albumin (Serva, Heidelberg, Germany) in PBS. The solution was emulsified with an equal part of Freund's adjuvant (Difco, Detroit, MI) in a final volume of 1 ml and administered at multiple intramuscular sites. Preimmune serum was taken just before immunization. After 4 weeks, the chicken was boostered and exsanguinated 14 days later.
High-performance thin-layer chromatography
GSLs were separated on high-performance thin-layer chromatography plates (HPTLC plates, size 10 cm × 10 cm, thickness 0.2 mm, Merck; Art. No. 5633). Neutral GSLs were chromatographed in solvent I (chloroform/methanol/water, 120/70/17, each by volume) and gangliosides in solvent II (chloroform/ methanol/water, 120/85/20, each by volume), the latter supplemented with 2 mM CaCl 2 . Neutral GSLs were visualized with orcinol (Svennerholm, 1956 ) and gangliosides with orcinol or resorcinol (Svennerholm, 1957) . IV 6 nLc4Cer-gangliosides of the HGG fraction were quantified by densitometry with a CD60 scanner (Desaga, Heidelberg, Germany) equipped with an IBM-compatible personal computer and densitometric software. Chromatographed bands were measured in reflectance mode at 580 nm (resorcinol) with a light beam slit of 0.1 × 2 mm.
Neutral GSLs from human granulocytes and MDAY-D2 cells as well as gangliosides from human granulocytes appear as double bands on TLCs as already described.
TLC overlay assay
Secondary rabbit anti-chicken IgY, goat anti-mouse IgG and IgM, and goat anti-rabbit IgG antisera, all affinity chromatographypurified and labeled with alkaline phosphatase, were purchased from Dianova (Hamburg, Germany) and used in a 1:2000 dilution (Duvar et al., 1997) . The TLC immunostaining procedure was carried out according to Magnani et al. (1982) with some modifications. After TLC of GSLs the silica gel was fixed with polyisobutylmethacrylate (Plexigum P28, Röhm, Darmstadt, Germany) as described by Müthing and Mühlradt (1988) . Two reviews concerning the details of the TLC immunostaining procedure have been published (Müthing, 1996 (Müthing, , 1998 .
Terminally α2-6-sialylated neolacto-series gangliosides were detected by the chicken polyclonal anti-Neu5Acα2-6Galβ1-4GlcNAc-R antibody. The HPTLC plate was soaked for 15 min with 1% (w/v) bovine serum albumin in PBS (solution A) and then overlayed for 1 h with the primary antibody diluted 1:1000 in solution A. The plate was washed three times with 0.05% (v/v) Tween 21 in PBS (solution B) and incubated for 1 h with alkaline phosphatase-labeled rabbit anti-chicken IgY antibody diluted in solution A. The plate was then washed three times with solvent B and once with glycine buffer (0.1 M glycine, 1 mM ZnCl 2 , 1 mM MgCl 2 , pH 10.4) to remove phosphate. Bound antibodies were visualized by color development of blue indigo-like stable stain after incubation of the plate with 0.05% (w/v) 5-bromo-4-chloro-3-indolylphosphate (Biomol, Hamburg, Germany) in glycine buffer.
The rViscumin binding activity toward GSLs was detected after prewashing the plate with 0.1 g/L Tween 80 in PBS (PBS-T80), followed by overlaying the chromatogram for 1 h with 1 µg/ml rViscumin diluted in PBS-T80. The plate was washed with solution B, incubated for 15 min with solution A, and then overlayed with the murine anti-rMLA monoclonal antibody TA5 (1 µg/ml in solution A). The next steps were performed as already described. Secondary alkaline phosphatase labeled anti-mouse IgG and IgM was used for the detection of bound mouse TA5 antibody.
The ricin overlay binding assay was performed according to the protocol described for rViscumin. Ricin was used in a working concentration of 1 µg/ml in PBS-T80; the polyclonal rabbit antiricin antibody was employed in 1:200 dilution and detected with alkaline phosphatase labeled secondary anti-rabbit antibody.
Determination of cellular quantities of IV 6 nLc4Cer
The amounts of IV 6 nLc4Cer expressed by HL-60 and 5637 cells were quantified by scanning of TLC bands stained with the anti-IV 6 nLc4Cer antibody. Defined quantities of HGG reference IV 6 nLc4Cer ganglioside (calibration curve) were scanned in comparison to ganglioside fractions of defined cell numbers ranging from 1 × 10 6 to 2 × 10 7 cells. The blue-colored immunostained double bands were scanned in reflectance mode at 630 nm. The numbers of IV 6 nLc4Cer molecules per cell were calculated by use of Avogadro's constant (6.02252 × 10 23 molecules per mol) and the known molecular weight of 1626 for IV 6 nLc4Cer substituted with C24-fatty acid (upper band, compound 1) and the molecular weight of 1516 for IV 6 nLc4Cer substituted with C16-fatty acid (lower band, compound 2).
Microwell adsorption assay
The microwell adsorption assays were carried out with neutral GSLs and gangliosides on polystyrene microtiter plates (MaxiSorp F96 immuno plates; Nunc) at room temperature. Microwells were loaded with GSLs in 100 µl methanol, starting with a defined GSL amount followed by three serial 1:2 dilutions. Neutral GSLs from human erythrocytes: 1.25, 2.5, 5, and 10 µg; neutral GSLs from human granulocytes: 1.88, 3.75, 7.5, and 15 µg; neutral GSLs from MDAY-D2: 2.5, 5, 10, and 20 µg; human granulocyte gangliosides and human brain gangliosides: 1.25, 2.5, 5, and 10 µg. Methanol was evaporated by exposure of the plate in a dry atmosphere for 45 min at 37°C. The solutions used were the same as described for the TLC overlay binding assay.
All incubation steps were performed in volumes of 100 µl per well. The GSL-coated microwells were incubated for 15 min with PBS-T80 and then provided with 1 µg of rViscumin dissolved in PBS-T80 (0.01 µg/µl). After 1 h incubation the wells were washed three times with solvent B, soaked for 15 min in solution A, and then loaded for 1 h with the murine anti-rMLA monoclonal antibody TA5 (1 µg/ml in solution A). The wells were washed three times with solvent B and incubated with alkaline phosphatase-labeled anti-mouse IgG and IgM secondary antibody diluted 1:2000 in solution A. After 1-h incubation and threefold washing with solution B, bound antibodies were visualized with di-sodium-4-nitrophenylphosphatehexahydrate (16 mM in 0.1 M glycine buffer pH 10.4). Enzyme activity was recorded after 20 min at 405 nm with an ELISA microplate autoreader (EL311, Bio-Tec Instruments, Winooski, VT).
